The prevalence of BRCA1/BRCA2 and ATM mutations was found to be greater than the reported rates of low-risk localized PCa patients by Na, R. et al. [9], i.e., 1.44%, and is consistent with the findings in the cohort analyzed by Marshall, C.H. et al. [10]—5.4%. The gene discussed is BRCA1; the disease is posterior cortical atrophy.